The recent results from the pivotal Phase 3 ROSELLA trial mark a significant development in the battle against platinum-resistant ovarian cancer. Corcept Therapeutics announced that the trial successfully demonstrated the efficacy of combining relacorilant with nab-paclitaxel chemotherapy,
The world of personalized cancer treatment has seen groundbreaking advancements with the introduction of combination immunotherapy, particularly in the realm of metastatic gastrointestinal (GI) cancers. Researchers at the National Cancer Institute (NCI) have developed a transformative approach that
Roche has recently entered into a groundbreaking multi-year collaboration with Oxford BioTherapeutics (OBT), valued at over a billion dollars, to spearhead the development of novel antibody-based cancer treatments. This significant partnership focuses on the creation of innovative therapies such as
Breast cancer survivors are growing in number, thanks to early detection and effective treatments. However, alongside their survival, an undercurrent of accelerated aging has been observed, raising questions about the long-term impacts of the disease and its treatments on biological aging. This
Research on cranial osteopathic manipulation for TBI treatment has received $2.17 million from the NIH. This funding supports Virginia Tech’s Pamela VandeVord and Edward Via College of Osteopathic Medicine’s Gunnar Brolinson. Their collective efforts aim to explore innovative non-invasive
Bioprinting has emerged as a revolutionary bioengineering technique that utilizes the principles of 3D printing to create tissue-like structures embedded with living cells. Since its inception in 1988, this technology has experienced tremendous growth, advancing from its original concept to today’s
